Welcome to DukeHealth.org.
Skip over navigation
  • Home
  • Patient and Visitor Info
  • Physicians
  • Services
  • Clinical Trials
  • Event Calendar
  • Locations
  • Health Library
  • About Duke Medicine

Quick Links

  • Appointments
  • HealthView Patient Login
  • Quality and Safety
Home > Physicians > Robertson, Cary N.
Jumbo Large Regular Text:
Print
Physicians

Cary N. Robertson, MD

Related Content

Locations

  • Duke Urology of Raleigh

Services

  • Minimally Invasive Urologic Surgery
  • Prostate Cancer
  • Urologic Cancers
  • Urologic Oncology

Health Library

  • Surviving and Thriving
  • A Tale of Three Prostates
  • Robots in the OR

Share

Cary N. Robertson, MD

Department / Division
Surgery / Urology

Address
3480 Wake Forest Road, Suite 506
Raleigh, NC 27609

Appointment Telephone
919-862-5600

Office Telephone
919-862-5600

Fax Telephone
919-862-5610

Training
  • MD, Tulane University School of Medicine (Louisiana), 1977

Residency
  • Surgery, University of Oregon Health Center, 1977-1978
  • Surgery, Duke University Medical Center, 1980-1981
  • Urologic Surgery, Duke University Medical Center, 1981-1985

Fellowship
  • Urologic Oncology (Fellow), Surgery Branch, National Cancer Institute (Maryland), 1985-1987
  • Urologic Oncology (Senior Investigator), Surgery Branch, National Cancer Institute (Maryland), 1987-1988

Clinical Interests
Urologic oncology, robot-assisted laparoscopic radial prostatectomy, high-intensity focused ultrasound therapy of prostate cancer, renal-cell cancer, partial nephrectomy, benign prostatic hyperplasia

Research Interests
1. High Intensity Focused Ultrasound Therapy of Prostate Cancer
2. Surgical Technique Improvement in Prostate Cancer
3. Clinical Predictors of Outcome in Prostate Cancer
4. Molecular Imaging and Genomics of Genitourinary Malignancies
5. Quality of Life measures in Genitourinary Malignancies

Industry Relationships and Collaborations (What's this?)

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

  • Aurora Funds
  • Bayer
  • Dendreon Corporation
  • EDAP TMS

Representative Publications
Blana, A; Robertson, CN; Brown, SC; Chaussy, C; Crouzet, S; Gelet, A; Conti, GN; Ganzer, R; Pasticier, G; Thuroff, S; Ward, JF. Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry. Prostate Cancer and Prostatic Diseases. 2012;15:256-259. (2012) Abstract

Motzer, RJ; Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Buyyounouski, MK; Carducci, MA; Chang, SS; Choueiri, TK; Gupta, S; Hancock, SL; Hudes, GR; Jonasch, E; Kuzel, TM; Lau, C; Levine, EG; Lin, DW; Margolin, KA; Michaelson, MD; Olencki, T; Pili, R; Ratliff, TW; Redman, BG; Robertson, CN; Ryan, CJ; Sheinfeld, J; Wang, J; Wilder, RB; National Comprehensive Cancer Network. Testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2012;10:502-535. (2012) Abstract

Stewart, SB; Bañez, LL; Robertson, CN; Freedland, SJ; Polascik, TJ; Xie, D; Koontz, BF; Vujaskovic, Z; Lee, WR; Armstrong, AJ; Febbo, PG; George, DJ; Moul, JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. Journal of Urology. 2012;187:103-108. (2012) Abstract

Wattson, DA; Chen, MH; Moul, JW; Moran, BJ; Dosoretz, DE; Robertson, CN; Polascik, TJ; Braccioforte, MH; Salenius, SA; D'Amico, AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. International Journal of Radiation: Oncology - Biology - Physics. 2012;82:e773-e779. (2012) Abstract

Westover, K; Chen, MH; Moul, J; Robertson, C; Polascik, T; Dosoretz, D; Katin, M; Salenius, S; D'Amico, AV. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU International. 2012;110:1116-1121. (2012) Abstract

Cotter, SE; Chen, MH; Moul, JW; Lee, WR; Koontz, BF; Anscher, MS; Robertson, CN; Walther, PJ; Polascik, TJ; D'Amico, AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-3932. (2011) Abstract

Ganzer, R; Robertson, CN; Ward, JF; Brown, SC; Conti, GN; Murat, FJ; Pasticier, G; Rebillard, X; Thuroff, S; Wieland, WF; Blana, A. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. BJU International. 2011;108:E196-E201. (2011) Abstract

Kimura, M; Bañez, LL; Schroeck, FR; Gerber, L; Qi, J; Satoh, T; Baba, S; Robertson, CN; Walther, PJ; Donatucci, CF; Moul, JW; Polascik, TJ. Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. Journal of Sexual Medicine. 2011;8:2935-2943. (2011) Abstract

Motzer, RJ; Agarwal, N; Beard, C; Bhayani, S; Bolger, GB; Carducci, MA; Chang, SS; Choueiri, TK; Hancock, SL; Hudes, GR; Jonasch, E; Josephson, D; Kuzel, TM; Levine, EG; Lin, DW; Margolin, KA; Michaelson, MD; Olencki, T; Pili, R; Ratliff, TW; Redman, BG; Robertson, CN; Ryan, CJ; Sheinfeld, J; Spiess, PE; Wang, J; Wilder, RB; National Comprehensive Cancer Network. Kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2011;9:960-977. (2011) Abstract

Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Moul, JW. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU International. 2011;108:44-48. (2011) Abstract

Tsivian, M; Mouraviev, V; Albala, DM; Caso, JR; Robertson, CN; Madden, JF; Polascik, TJ. Clinical predictors of renal mass pathological features. BJU International. 2011;107:735-740. (2011) Abstract

Caire, AA; Sun, L; Lack, BD; Lum, K; Tang, P; Stackhouse, DA; Robertson, CN; Mouraviev, V; Polascik, TJ; Albala, DM; Moul, JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer and Prostatic Diseases. 2010;13:248-251. (2010) Abstract

Caire, AA; Sun, L; Robertson, CN; Polascik, TJ; Maloney, KE; George, DJ; Price, MM; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology. 2010;75:1122-1127. (2010) Abstract

Choueiri, TK; Chen, MH; D'Amico, AV; Sun, L; Nguyen, PL; Hayes, JH; Robertson, CN; Walther, PJ; Polascik, TJ; Albala, DM; Moul, JW. Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer. 2010;116:1887-1892. (2010) Abstract

D'Amico, AV; Chen, MH; Sun, L; Lee, WR; Mouraviev, V; Robertson, CN; Walther, PJ; Polascik, TJ; Albala, DM; Moul, JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU International. 2010;106:1618-1622. (2010) Abstract

Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Albala, DM; Donatucci, CF; Moul, JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. Journal of Urology. 2010;183:946-950. (2010) Abstract

Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Albala, DM; Donatucci, CF; Moul, JW. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. Urology. 2010;76:1058-1062. (2010) Abstract

Tsivian, M; Moreira, DM; Caso, JR; Mouraviev, V; Madden, JF; Bratslavsky, G; Robertson, CN; Albala, DM; Polascik, TJ. Predicting occult multifocality of renal cell carcinoma. European Urology. 2010;58:118-126. (2010) Abstract

Uhlman, MA; Sun, L; Stackhouse, DA; Caire, AA; Polascik, TJ; Robertson, CN; Madden, J; Vollmer, R; Albala, DM; Moul, JW. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?. Urology. 2010;75:460-466. (2010) Abstract

Uhlman, MA; Sun, L; Stackhouse, DA; Polascik, TJ; Mouraviev, V; Robertson, CN; Albala, DM; Moul, JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. Journal of Urology. 2010;183:997-1001. (2010) Abstract

Blana, A; Brown, SC; Chaussy, C; Conti, GN; Eastham, JA; Ganzer, R; Murat, FJ; Pasticier, G; Rebillard, X; Rewcastle, JC; Robertson, CN; Thuroff, S; Ward, JF. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU International. 2009;104:1058-1062. (2009) Abstract

Caire, AA; Sun, L; Ode, O; Stackhouse, DA; Maloney, K; Donatucci, C; Mouraviev, V; Polascik, TJ; Robertson, CN; Albala, DM; Moul, JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?. Urology. 2009;74:643-647. (2009) Abstract

D'Alonzo, RC; Gan, TJ; Moul, JW; Albala, DM; Polascik, TJ; Robertson, CN; Sun, L; Dahm, P; Habib, AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. Journal of Clinical Anesthesia. 2009;21:322-328. (2009) Abstract

Motzer, RJ; Agarwal, N; Beard, C; Bolger, GB; Boston, B; Carducci, MA; Choueiri, TK; Figlin, RA; Fishman, M; Hancock, SL; Hudes, GR; Jonasch, E; Kessinger, A; Kuzel, TM; Lange, PH; Levine, EG; Margolin, KA; Michaelson, MD; Olencki, T; Pili, R; Redman, BG; Robertson, CN; Schwartz, LH; Sheinfeld, J; Wang, J. NCCN clinical practice guidelines in oncology: kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7:618-630. (2009) Abstract

Motzer, RJ; Agarwal, N; Beard, C; Bolger, GB; Boston, B; Carducci, MA; Choueiri, TK; Figlin, RA; Fishman, M; Hancock, SL; Hudes, GR; Jonasch, E; Kessinger, A; Kuzel, TM; Lange, PH; Levine, EG; Margolin, KA; Michaelson, MD; Olencki, T; Pili, R; Redman, BG; Robertson, CN; Schwartz, LH; Sheinfeld, J; Wang, J. NCCN clinical practice guidelines in oncology: testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7:672-693. (2009) Abstract

Stackhouse, DA; Sun, L; Schroeck, FR; Jayachandran, J; Caire, AA; Acholo, CO; Robertson, CN; Albala, DM; Polascik, TJ; Donatucci, CF; Maloney, KE; Moul, JW. Factors predicting prostatic biopsy Gleason sum under grading. Journal of Urology. 2009;182:118-122. (2009) Abstract

Sun, L; Caire, AA; Robertson, CN; George, DJ; Polascik, TJ; Maloney, KE; Walther, PJ; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. Journal of Urology. 2009;182:2242-2248. (2009) Abstract

Xu, DD; Sun, SD; Wang, F; Sun, L; Stackhouse, D; Polascik, T; Albala, DM; Moul, JW; Caire, A; Robertson, CN. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009;74:654-658. (2009) Abstract

Bartsch, G; Horninger, W; Klocker, H; Pelzer, A; Bektic, J; Oberaigner, W; Schennach, H; Schäfer, G; Frauscher, F; Boniol, M; Severi, G; Robertson, C; Boyle, P; Tyrol Prostate Cancer Screening Group. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU International. 2008;101:809-816. (2008) Abstract

Demark-Wahnefried, W; Polascik, TJ; George, SL; Switzer, BR; Madden, JF; Ruffin, MT; Snyder, DC; Owzar, K; Hars, V; Albala, DM; Walther, PJ; Robertson, CN; Moul, JW; Dunn, BK; Brenner, D; Minasian, L; Stella, P; Vollmer, RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:3577-3587. (2008) Abstract

Isariyawongse, BK; Sun, L; Bañez, LL; Robertson, C; Polascik, TJ; Maloney, K; Donatucci, C; Albala, D; Mouraviev, V; Madden, JF; Moul, JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008;72:882-886. (2008) Abstract

Price, MM; Hamilton, RJ; Robertson, CN; Butts, MC; Freedland, SJ. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71:787-791. (2008) Abstract

Schroeck, FR; Krupski, TL; Sun, L; Albala, DM; Price, MM; Polascik, TJ; Robertson, CN; Tewari, AK; Moul, JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. European Urology. 2008;54:785-793. (2008) Abstract

Schroeck, FR; Sun, L; Freedland, SJ; Jayachandran, J; Robertson, CN; Moul, JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Diseases. 2008;11:371-376. (2008) Abstract

Marguet, C; Raj, GV; Brashears, JH; Anscher, MS; Ludwig, K; Mouraviev, V; Robertson, CN; Polascik, TJ. Rectourethral fistula after combination radiotherapy for prostate cancer. Urology. 2007;69:898-901. (2007) Abstract

Moul, JW; Sun, L; Hotaling, JM; Fitzsimons, NJ; Polascik, TJ; Robertson, CN; Dahm, P; Anscher, MS; Mouraviev, V; Pappas, PA; Albala, DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. Journal of Urology. 2007;177:499-503. (2007) Abstract

Mouraviev, V; Nosnik, I; Robertson, C; Albala, D; Walther, P; Polascik, TJ. Comparative financial analysis of minimally invasive surgery to open surgery for small renal tumours < or =3.5 cm: a single institutional experience. European Urology. 2007;51:715-720. (2007) Abstract

Mouraviev, V; Nosnik, I; Sun, L; Robertson, CN; Walther, P; Albala, D; Moul, JW; Polascik, TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007;69:311-314. (2007) Abstract

Robertson, C; Link, CL; Onel, E; Mazzetta, C; Keech, M; Hobbs, R; Fourcade, R; Kiemeney, L; Lee, C; Boyle, P; McKinlay, JB. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. British Journal of Urology (BJU) International. 2007;99:347-354. (2007) Abstract

Sun, L; Moul, JW; Hotaling, JM; Rampersaud, E; Dahm, P; Robertson, C; Fitzsimons, N; Albala, D; Polascik, TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. British Journal of Urology (BJU) International. 2007;99:753-757. (2007) Abstract

Tseng, TY; Cancel, QV; Fesperman, SF; Kuebler, HR; Sun, L; Robertson, CN; Polascik, TJ; Moul, JW; Vieweg, J; Albala, DM; Dahm, P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. Journal of Urology. 2007;177:1318-1323. (2007) Abstract

Anscher, MS; Clough, R; Robertson, CN; Prosnitz, LR; Dahm, P; Walther, P; Donatucci, CF; Albala, DM; Febbo, P; George, DJ; Sun, L; Moul, JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer and Prostatic Diseases. 2006;9:254-260. (2006) Abstract

Motzer, RJ; Bolger, GB; Boston, B; Carducci, MA; Fishman, M; Hancock, SL; Hauke, RJ; Hudes, GR; Jonasch, E; Kantoff, P; Kuzel, TM; Lange, PH; Levine, EG; Logothetis, C; Margolin, KA; Pohar, K; Redman, BG; Robertson, CN; Samlowski, WE; Sheinfeld, J; National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2006;4:1072-1081. (2006) Abstract

Motzer, RJ; Bolger, GB; Boston, B; Carducci, MA; Fishman, M; Hancock, SL; Hauke, RJ; Hudes, GR; Jonasch, E; Kantoff, P; Kuzel, TM; Lange, PH; Levine, EG; Logothetis, C; Margolin, KA; Pohar, KS; Redman, BG; Robertson, CN; Samlowski, WE; Sheinfeld, J; National Comprehensive Cancer Network. Testicular cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2006;4:1038-1058. (2006) Abstract

Motzer, RJ; Bahnson, RR; Boston, B; Carducci, MA; Fishman, M; Hancock, SL; Hauke, RJ; Hudes, GR; Kantoff, P; Kuzel, TM; Lange, PH; Levine, EG; Logothetis, C; Margolin, KA; Redman, BG; Richey, S; Robertson, CN; Samlowski, WE; Sheinfeld, J; Urban, DA; National Comprehensive Cancer Network. Testicular cancer. Clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2005;3:52-76. (2005) Abstract

Motzer, RJ; Carducci, MA; Fishman, M; Hancock, SL; Hauke, RJ; Hudes, GR; Kantoff, P; Kuzel, TM; Lange, PH; Levine, EG; Logothetis, C; Margolin, KA; Pili, R; Pohar, KS; Redman, BG; Richey, S; Robertson, CN; Samlowski, WE; Sheinfeld, J; Urban, DA; National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines. Journal of the National Comprehensive Cancer Network : JNCCN. 2005;3:84-93. (2005) Abstract

Price, DT; Coleman, RE; Liao, RP; Robertson, CN; Polascik, TJ; DeGrado, TR. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. Journal of Urology. 2002;168:273-280. (2002) Abstract

DeGrado, TR; Coleman, RE; Wang, S; Baldwin, SW; Orr, MD; Robertson, CN; Polascik, TJ; Price, DT. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Research. 2001;61:110-117. (2001) Abstract

Demark-Wahnefried, W; Price, DT; Polascik, TJ; Robertson, CN; Anderson, EE; Paulson, DF; Walther, PJ; Gannon, M; Vollmer, RT. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001;58:47-52. (2001) Abstract

Ogawa, Y; Nakagami, Y; Ishizaki, R; Yoshida, H; Parkinson, KM; Robertson, CN; Paulson, DF. Heat shock protein 70 (HSP70) does not prevent the inhibition of cell growth in DU-145 cells treated with TGF-beta1. Anticancer Research: international journal of cancer research and treatment. 2001;21:3341-3347. (2001) Abstract

Young, MD; Dahm, P; Robertson, CN. Prostatic sarcoma with rapid tumor progression after nerve sparing radical cystoprostatectomy. Journal of Urology. 2001;166:994. (2001) Abstract

Denmark-Wahnefried, W; Schildkraut, JM; Thompson, D; Lesko, SM; McIntyre, L; Schwingl, P; Paulson, DF; Robertson, CN; Anderson, EE; Walther, PJ. Early onset baldness and prostate cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 2000;9:325-328. (2000) Abstract

Ahearn, GS; Bedlack, RS; Price, DT; Robertson, CN; Morgenlander, JC. Transient lumbosacral polyradiculopathy after prostatectomy: association with spinal stenosis. Southern Medical Journal. 1999;92:809-811. (1999) Abstract

Kim, SP; Bennett, CL; Chan, C; Chmiel, J; Falcone, D; Knight, SJ; Kuzel, T; Davis, TC; Elstein, AS; Moran, E; Robertson, CN; Smith, JS. QOL and outcomes research in prostate cancer patients with low socioeconomic status. Oncology. 1999;13:823-832. (1999) Abstract

Padilla-Nash, HM; Nash, WG; Padilla, GM; Roberson, KM; Robertson, CN; Macville, M; Schröck, E; Ried, T. Molecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping. Genes Chromosomes and Cancer. 1999;25:53-59. (1999) Abstract

Contact Us | Careers | Privacy Policy | Make a Gift | Site Map | RSS Feeds | En Español | Mobile Site | Help
Duke Medicine | Duke School of Medicine | Duke Children's | Duke University
Toll-Free: 888-ASK-DUKE (888-275-3853)
Copyright © 2004-2013 Duke University Health System

About This Page

Updated: July 5, 2011
Published: Dec. 12, 2006
URL: http://www.dukehealth.org/physicians/cary_n_robertson